-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HvR68Aw1o7CO8gfKStnSwKeZFTYevjMUYcmadcg0OypoQkI5TIi+pHhufdPuvyoQ J75xdb4NXI15/CZ969SAQA== 0000728889-96-000020.txt : 19960410 0000728889-96-000020.hdr.sgml : 19960410 ACCESSION NUMBER: 0000728889-96-000020 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19960209 SROS: NONE SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: KV PHARMACEUTICAL CO /DE/ CENTRAL INDEX KEY: 0000057055 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 430618919 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-12338 FILM NUMBER: 96513901 BUSINESS ADDRESS: STREET 1: 2503 S HANLEY RD CITY: ST LOUIS STATE: MO ZIP: 63144 BUSINESS PHONE: 3146456600 MAIL ADDRESS: STREET 1: 2503 S HANLEY RD CITY: ST LOUIS STATE: MO ZIP: 63144 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: OPPENHEIMER MANAGEMENT CORP CENTRAL INDEX KEY: 0000728889 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: TWO WORLD TRADE CENTER STREET 2: 34TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10048-0203 BUSINESS PHONE: 212-323-0200 MAIL ADDRESS: STREET 1: TWO WORLD TRADE CENTER STREET 2: 34TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10048-0203 SC 13G 1 KV PHARMACEUTICAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) K-V Pharmaceutical Co. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 482740206 (CUSIP Number) Check the following box if a fee /X/ is being paid with this statement (A fee is not required only if the filing person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") of otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on following pages) Page 1 of 7 Pages - ---------------------------- ------------------------- Cusip No. 481740206 13G Page 2 of 7 Pages - ---------------------------- ------------------------- - ------------------------------------------------------------------- 1. NAME OF REPORTING PERSON S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON OppenheimerFunds, Inc. I.R.S. NO. 13-2527171 - ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP * A / / B / X / - ------------------------------------------------------------------- 3. SEC USE ONLY - ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Colorado - ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY ----------------------------------------------- OWNED BY 6. SHARED VOTING POWER EACH 0 REPORTING ----------------------------------------------- PERSON WITH 7. SOLE DISPOSITIVE POWER 0 ----------------------------------------------- 8. SHARED DISPOSITIVE POWER 376,800 - ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 376,800 - ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES * - ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.55% - ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON IA - ------------------------------------------------------------------- * SEE INSTRUCTIONS BEFORE FILLING OUT! - ---------------------------- ------------------------- Cusip No. 482740206 13G Page 3 of 7 Pages - ---------------------------- ------------------------- - ------------------------------------------------------------------- 1. NAME OF REPORTING PERSON S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Oppenheimer Global Fund I.R.S. NO. 13-2649093 - ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP * A / / B / X / - ------------------------------------------------------------------- 3. SEC USE ONLY - ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Massachusetts - ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 376,800 BENEFICIALLY ----------------------------------------------- OWNED BY 6. SHARED VOTING POWER EACH 0 REPORTING ----------------------------------------------- PERSON WITH 7. SOLE DISPOSITIVE POWER 0 ----------------------------------------------- 8. SHARED DISPOSITIVE POWER 376,800 - ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 376,800 - ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES * - ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.55% - ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON IV - ------------------------------------------------------------------- * SEE INSTRUCTIONS BEFORE FILLING OUT! SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Check the following box if a fee is being paid with this statement /X/ Item 1(a) Name of Issuer: K-V Pharmaceutical Co. Item 1(b) Address of Issuer's Principal Executive Offices: 2503 S. Hanley Road St. Louis, MO 63144 Item 2(a) Name of Person Filing: OppenheimerFunds, Inc. Item 2(b) Address of Principal Business Office: Two World Trade Center, Suite 3400 New York, New York 10048-0203 Item 2(c) Citizenship: Inapplicable Item 2(d) Title of Class of Securities: Class A Common Stock Item 2(e) CUSIP Number: 482740206 Item 3(e) XInvestment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4(a) Amount Beneficially Owned: 376,800 shares Item 4(b) Percent of Class: 5.55% Item 4(c)(i) Sole Power to vote or to direct the vote - 0 Item 4(c)(ii) Shared power to vote or to direct the vote - 0 Item 4(c)(iii) Sole power to dispose or to direct the disposition of - 0 Item 4(c)(iv) Shared power to dispose or to direct the disposition of - 376,800 shares Item 5 Ownership to Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than 5% of the class of securities, check the following: / / Item 6 Ownership of More than Five Percent on Behalf of Another Person: See Exhibit A hereto Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company: Inapplicable Item 8 Identification and Classification of Members of the Group: Inapplicable Item 9 Notice of Dissolution of Group: Inapplicable Item 10 Certification: By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 9, 1996 Signature: /s/ Merryl Hoffman ------------------------------------ Name/Title: Merryl Hoffman, Vice President EXHIBIT A The Board of Directors or Trustees of the registered investment companies managed by OppenheimerFunds, Inc. ("OFI") and owning shares of the issuer can direct the disposition of dividends received by such funds and can dispose of such securities. Additionally, OFI shares the power to dispose of such securities with the Board of Directors or Trustees of such funds; however, the Board of Directors or Trustees of such fund has delegated these responsibilities to OFI as the fund's investment advisor under its investment advisory agreement. OFI has an interest relating to five (5%) percent or more of such securities as disclosed on Page 2 hereof, by virtue of the interest of five percent (5%) or more of such securities by Oppenheimer Global Fund, as disclosed on pages 3 and 4 hereof. OFI disclaims ownership of such securities, except as expressly stated herein. EXHIBIT B The undersigned investment company hereby acknowledges and agrees that a report on Schedule 13G being filed by OppenheimerFunds, Inc. or about the date hereof, relating to the Common Stock of K-V Phamaceutical Co., is filed on behalf of the undersigned. Dated: February 9, 1996 Oppenheimer Global Fund By: /s/ Robert G. Zack ___________________________________ Robert G. Zack Assistant Secretary February 8, 1996 -----END PRIVACY-ENHANCED MESSAGE-----